David M. Brown
#173,970
Most Influential Person Now
David M. Brown's AcademicInfluence.com Rankings
David M. Brownmedical Degrees
Medical
#3605
World Rank
#4088
Historical Rank
Ophthalmology
#76
World Rank
#99
Historical Rank
David M. Brownphilosophy Degrees
Philosophy
#10564
World Rank
#14490
Historical Rank
Ontology
#144
World Rank
#161
Historical Rank
Logic
#7430
World Rank
#9185
Historical Rank
Download Badge
Medical Philosophy
David M. Brown's Degrees
- Bachelors Biology University of California, Berkeley
- Doctorate Medicine Stanford University
Similar Degrees You Can Earn
Why Is David M. Brown Influential?
(Suggest an Edit or Addition)David M. Brown's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Ranibizumab versus verteporfin for neovascular age-related macular degeneration. (2006) (3214)
- Ranibizumab for neovascular age-related macular degeneration. (2006) (2402)
- Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. (2012) (1883)
- Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. (2012) (1426)
- Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. (2009) (1293)
- Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. (2010) (1011)
- Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. (2008) (854)
- Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. (2013) (757)
- Intravitreal aflibercept for diabetic macular edema. (2014) (721)
- Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. (2014) (686)
- ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (2006) (670)
- Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. (2007) (518)
- Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. (2013) (505)
- Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. (2011) (454)
- Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. (2012) (450)
- HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. (2019) (442)
- Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. (2015) (436)
- Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. (2011) (435)
- One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. (2012) (368)
- Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. (2011) (355)
- A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. (2009) (326)
- Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. (2013) (316)
- Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. (2016) (308)
- Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. (2007) (293)
- Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. (2014) (288)
- Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. (2015) (270)
- Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration (2011) (267)
- Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. (2014) (240)
- Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results. (2015) (234)
- Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. (2012) (224)
- Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. (2007) (212)
- Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. (2016) (211)
- Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. (2020) (186)
- Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. (2010) (162)
- The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. (2011) (141)
- Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials. (2015) (128)
- Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. (2013) (122)
- Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the “flying saucer” sign) (2010) (117)
- Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. (2013) (115)
- ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION: The Importance of Viridans Streptococci (2011) (98)
- Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice. (2016) (90)
- RANIBIZUMAB IN PREPROLIFERATIVE (ISCHEMIC) CENTRAL RETINAL VEIN OCCLUSION: The Rubeosis Anti-VEGF (RAVE) Trial (2014) (90)
- Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial) (2014) (86)
- Randomized Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: 2-Year Results of the TREX-AMD Study. (2017) (85)
- Precise montaging and metric quantification of retinal surface area from ultra-widefield fundus photography and fluorescein angiography. (2014) (80)
- Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. (2011) (77)
- Venous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disorders (2021) (75)
- Distribution of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study. (2017) (74)
- Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. (2013) (71)
- Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes. (2017) (69)
- ANATOMICAL MEASURES AS PREDICTORS OF VISUAL OUTCOMES IN RANIBIZUMAB-TREATED EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (2013) (68)
- Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials (2022) (60)
- Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials (2022) (60)
- Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study. (2017) (59)
- Phase I Trial of Anti-Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration. (2017) (56)
- Cystoid macular edema secondary to albumin-bound paclitaxel therapy. (2008) (56)
- Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases. (2017) (56)
- Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial. (2018) (50)
- Ranibizumab for Neovascular Age-Related Macular Degeneration (AMD): Optical Coherence Tomography (OCT) vs. Visual Acuity (VA) Changes in PIER Study (2008) (50)
- Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies. (2018) (47)
- Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy (2021) (45)
- Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial. (2019) (45)
- Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes. (2019) (42)
- PROGRESSIVE RETINAL NONPERFUSION IN ISCHEMIC CENTRAL RETINAL VEIN OCCLUSION (2015) (38)
- Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial (2017) (38)
- Recurrent Mycobacterium marinum tenosynovitis of the wrist mimicking extraarticular synovial chondromatosis on MR images (2004) (38)
- Suprachoroidal Triamcinolone Acetonide for Diabetic Macular Edema: The HULK Trial. (2018) (36)
- The Potential Importance of Detection of Neovascular Age-Related Macular Degeneration When Visual Acuity Is Relatively Good (2017) (33)
- KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema (2022) (32)
- Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration: A Phase 1 Dose-Escalation Study (2017) (32)
- Natural History of Drusenoid Pigment Epithelial Detachment Associated with Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report No. 17. (2019) (30)
- SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. (2013) (29)
- ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION: Role of Prophylactic Topical Ophthalmic Antibiotics (2016) (28)
- Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study (2017) (27)
- OUTCOMES OF MACULAR HOLE SURGERIES FOR MACULAR TELANGIECTASIA TYPE 2 (2014) (26)
- The effect of pregnancy on diabetic retinopathy (2012) (24)
- Peripheral Laser for Recalcitrant Macular Edema Owing to Retinal Vein Occlusion: The WAVE Trial. (2017) (22)
- Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration. (2015) (22)
- Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study. (2017) (22)
- Relationship Between Retinal Fractal Dimension and Non-perfusion in Diabetic Retinopathy on Ultra-Wide Field Fluorescein Angiography. (2019) (22)
- Changes in retinal ischaemic index correlate with recalcitrant macular oedema in retinal vein occlusion: WAVE study (2018) (21)
- Lucentis® using Visudyne® study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration (2010) (21)
- COMPARISON OF SPECTRAL-DOMAIN AND TIME-DOMAIN OPTICAL COHERENCE TOMOGRAPHY IN THE DETECTION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION ACTIVITY (2014) (20)
- Intravitreal A fl ibercept for Diabetic Macular Edema (2014) (20)
- Use of nepafenac (Nevanac®) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections (2010) (19)
- Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD. (2013) (18)
- Classification of Regions of Nonperfusion on Ultra-widefield Fluorescein Angiography in patients with Diabetic Macular Edema. (2019) (18)
- SEVERITY OF DIABETIC MACULAR EDEMA CORRELATES WITH RETINAL VASCULAR BED AREA ON ULTRA-WIDE FIELD FLUORESCEIN ANGIOGRAPHY: DAVE Study. (2020) (17)
- Aqueous Cytokine Expression and Higher-Order OCT Biomarkers: Assessment of the Anatomic-Biologic Bridge in the IMAGINE DME Study. (2020) (17)
- Longitudinal Assessment of Ellipsoid Zone Integrity, Subretinal Hyperreflective Material, and Sub-RPE Disease in Neovascular AMD. (2021) (16)
- CHOROIDAL NEOVASCULARIZATION SECONDARY TO ALEXANDRITE LASER EXPOSURE. (2016) (16)
- Long-term stability of circumferential silicone sponge scleral buckling exoplants. (2006) (15)
- Suprachoroidal Space Alterations Following Delivery of Triamcinolone Acetonide: Post-Hoc Analysis of the Phase 1/2 HULK Study of Patients With Diabetic Macular Edema. (2018) (15)
- Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes: A Randomized Clinical Trial. (2021) (14)
- Noncompliance in Prospective Retina Clinical Trials: Analysis of factors predicting loss to follow up. (2020) (14)
- Imaging Characteristics of Choroidal Neovascular Lesions in the AREDS2-HOME Study: Report Number 4. (2019) (14)
- Outcomes of Diabetic Macular Edema Patients by Baseline Hemoglobin A1c: Analyses from VISTA and VIVID. (2017) (12)
- Current Best Clinical Practices—Management of Neovascular AMD (2017) (12)
- Agnathia and Associated Malformations: A Case Report (1990) (11)
- Ranibizumab for diabetic macular edema. Author reply. (2013) (9)
- Retinal vascular bed area on ultra-wide field fluorescein angiography indicates the severity of diabetic retinopathy (2021) (9)
- Elevated Choroidal Thickness and Central Serous Chorioretinopathy in the Fellow Eyes of Patients with Circumscribed Choroidal Hemangioma (2017) (9)
- Visual Acuity Variability: Comparing Discrepancies between Snellen and ETDRS Measurements among Subjects Entering Prospective Trials. (2020) (9)
- Subgroup Analysis of First–Year Results of ANCHOR: A Phase III, Double–Masked, Randomized Comparison of Ranibizumab and Verteporfin Photodynamic Therapy for Predominantly Classic Choroidal Neovascularization Related to Age–Related Macular Degeneration (2006) (8)
- Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results (2020) (8)
- MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants With nAMD and Persistent Retinal Fluid. (2022) (8)
- Headache or Eye Pain as the Presenting Feature of Uveal Melanoma (2013) (7)
- Selected clinical comparisons of spectral domain and time domain optical coherence tomography. (2009) (7)
- Expanded Clinical Spectrum of Pentosan Polysulfate Maculopathy: a Macula Society Collaborative Study. (2021) (6)
- Longitudinal Assessment of Ellipsoid Zone Integrity, Subretinal Hyperreflective Material, and Subretinal Pigment Epithelium Disease in Neovascular Age-Related Macular Degeneration (2021) (5)
- GRANULAR HYPERREFLECTIVE SPECKS BY SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY AS SIGNS OF WEST NILE VIRUS INFECTION: THE STARDUST SIGN. (2015) (5)
- Ranibizumab (Lucentis) in Neovascular Age-Related Macular Degeneration (AMD): Subgroup Analysis of Year 1 PIER Efficacy Data (2007) (5)
- INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA (2022) (5)
- Exploring the angiographic-biologic phenotype in the IMAGINE study: quantitative UWFA and cytokine expression (2021) (4)
- THE TEXAS TACO TECHNIQUE FOR INTERNAL LIMITING MEMBRANE FLAP IN LARGE FULL-THICKNESS MACULAR HOLES: A Short-Term Pilot Study. (2020) (4)
- Not All Retina Is Created Equal: Metabolic Quantification of Ultra-Widefield Images. (2015) (4)
- RANIBIZUMAB VERSUS VERTEPORPHIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (2006) (3)
- NEW BIOMARKER QUANTIFYING THE EFFECT OF ANTI-VEGF THERAPY IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY ON ULTRAWIDE FIELD FLUORESCEIN ANGIOGRAPHY (2021) (3)
- Author reply: To PMID 23084240. (2014) (3)
- VEGF Trap-Eye In CRVO: Primary Endpoint Results Of The Phase 3 COPERNICUS Study (2011) (3)
- New directions in RVO treatment: Recent data have improved our understanding of BRVO and CRVO to better manage our patients (2010) (2)
- CNV lesion characteristics as a predictor of visual outcome in wet AMD patients receiving combination therapy of intravitreal anti-VEGF therapy and topical Squalamine lactate ophthalmic solution. (2016) (2)
- Purtscher-like retinopathy associated with pemphigus vulgaris. (2013) (2)
- Correlation between changes in OCT and visual acuity in the management of neovascular AMD: Does subretinal fluid matter? (2013) (2)
- Anti-VEGF agents in the treatment of neovascular AMD (2007) (2)
- Advancing the Detection and Management of Diabetic Retinopathy with Ultra-widefield Retinal Imaging (2017) (2)
- The Superdose Anti-VEGF (SAVE) Trial: 2.0-mg Intravitreal Ranibizumab for Recalcitrant Neovascular AMD, Two Year Endpoint Results (2012) (2)
- Reply: To PMID 24914476. (2015) (2)
- Multicenter, Prospective Trial Comparing Treat & Extend to Monthly Dosing in Neovascular AMD Management: TREX-AMD 12-Month Outcomes (2015) (2)
- The Association of Fluid Volatility With Subretinal Hyperreflective Material and Ellipsoid Zone Integrity in Neovascular AMD (2022) (2)
- Ranibizumab for Diabetic Macular Edema (DME): 24-Month Efficacy and Safety Results of RISE - a Phase 3 Randomized Controlled Trial (2011) (2)
- Intravitreal Aflibercept Injection in Central Retinal Vein Occlusion: 1-year Results of the Phase 3 COPERNICUS Study (2012) (1)
- Association of Aqueous Cytokine Profile and Extracted OCT Features in Diabetic Macular Edema: Assessment of the Anatomic-Biologic Bridge (2020) (1)
- Exploring the potential of combination therapies for DME (2009) (1)
- Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema. (2018) (1)
- Longitudinal Changes in Aqueous Humor Cytokines in Diabetic Macular Edema Treated with Anti-Vascular Endothelial Growth Factor Therapy (2020) (1)
- The LUV Trial: Ultra-low Fluence Verteporfin (VISUDYNE®) Photodynamic Therapy (vPDT) Combined with Intravitreal Ranibizumab (LUCENTIS®) Versus Ranibizumab Monotherapy (2009) (1)
- Quantification of ultra-widefield retinal images (2014) (1)
- Disorders of the Vitreous and Vitreoretinal Interface (2006) (1)
- Correlation of Ultra-widefield Fluorescein Angiographic Features with Intraocular Cytokine Expression in Diabetic Macular Edema: Exploring the Angiographic-Biologic Phenotype (2020) (1)
- Author reply: To PMID 23084240. (2014) (1)
- SAVE (Superdose AntiVEgf) Trial - 2.0-mg Intravitreal Ranibizumab For Recalcitrant Neovascular Age-related Macular Degeneration (2011) (1)
- Quantification of Retinal Surface-Area from Montaged Ultra-Widefield Fundus Photography (2014) (0)
- Macular Edema in Ischemic Central Retinal Vein Occlusion Modified by Intravitreal Ranibizumab (2006) (0)
- Correlation of Qualitative and Quantitative OCT With Visual Acuity Outcomes in Treatment-Naïve Patients in the SAILOR 1 Study (2009) (0)
- A Phase 1 Safety Study of an Orally Available Tyrosine Kinase Inhibitor X-82 in Previously Treated Wet AMD Patients (2015) (0)
- Longitudinal Assessment of Intraocular Cytokine Expression in Retinal Venous Occlusive Disease Following Anti-VEGF Therapy (2020) (0)
- Correlation of Intraocular Cytokine Expression with Higher Order OCT Features in Retinal Venous Occlusive Disease (2020) (0)
- Computational Imaging Biomarker Correlation with Intraocular Cytokine Expression in Diabetic Macular Edema (2022) (0)
- Nerve Fiber Layer Thickness (0)
- New Insights Into the Management of Diabetic Macular Edema and Related Conditions (2009) (0)
- Relationship between distance-weighted peripheral non-perfusion and diabetic macular edema (2015) (0)
- Detection of choroidal neovascular membranes using OCT Angiography: Learnings from the PROCON Study (2019) (0)
- Case presentations: Crvo and brvo: Crvo management (2010) (0)
- Dermatopathologic and Optical Coherence Tomography “Cracked Mud Sign” in Pseudoxanthoma Elasticum. (2018) (0)
- Aflibercept for treatment of diabetic macular edema: Promising 1-year data from a phase 2 study (2011) (0)
- Diabetic retinopathy: How and when to screen (1996) (0)
- Impact of retinal fluid-free months on outcomes in nAMD: a treatment agnostic analysis of the HAWK and HARRIER studies. (2022) (0)
- IMPACT OF RETINAL FLUID-FREE MONTHS ON OUTCOMES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (2023) (0)
- Considerations for Short-and Long-Term Management Individualizing Therapy for Patients With Neovascular AMD and DME : CME (2014) (0)
- Author reply: To PMID 25012934. (2015) (0)
- Efficacy and Safety of Ranibizumab (LUCENTIS®) for the Treatment of Choroidal Neovascularization Not Due to Age-Related Macular Degeneration: 6-Month Data From a Randomized Clinical Trial (2009) (0)
- Microplasmin shows promise for vitreomacular traction treatment: Microplasmin dissolves the protein structure linking vitreous to the retina (2008) (0)
- Baseline retinal vascular bed area on ultra-wide field fluorescein angiography correlates with the anatomical outcome of diabetic macular oedema to ranibizumab therapy: two-year analysis of the DAVE Study (2022) (0)
- Prior Anti-VEGF Use Did Not Affect Outcomes in VIVID / VISTA Patients (2014) (0)
- LONG-TERM STABILITY OF CIRCUMFERENTIAL SILICONE SPONGE SCLERAL BUCKLING EXOPLANTS (2006) (0)
- Patient with persistent intraretinal cysts (2010) (0)
- The impact of recent regulatory decisions regarding the iluvien intravitreal implant (2012) (0)
- Distribution of Nonperfusion Area on Ultra Widefield Angiography in Eyes with Diabetic Macular Edema: DAVE Study (2017) (0)
- Considering Anti-VEGF therapies for vein occlusions (2009) (0)
- Prospective Trial Comparing Ranibizumab Monthly to Treat & Extend With & Without Angiography-Guided Laser for DME: TREX-DME 1 Year Outcomes (2016) (0)
- RETINAL VASCULAR BED AREA IN EYES WITH RETINAL VEIN OCCLUSION ON ULTRA-WIDEFIELD FLUORESCEIN ANGIOGRAPHY (2022) (0)
- Author reply. (2014) (0)
- Patient With Persistent Intraretinal Cysts SD-OCT imaging revealed further details for the management of this case. (2010) (0)
- Intravitreal aflibercept for proliferative diabetic retinopathy (2017) (0)
- USE OF OPTICAL COHERENCE TOMOGRAPHY IN DETECTING RETINAL TEARS IN ACUTE, SYMPTOMATIC POSTERIOR VITREOUS DETACHMENT (2022) (0)
- Case presentations: CRVO and BRVO: Persistent CRVO in a monocular patient (2010) (0)
- Full Thickness Macular Hole Development After Rhegmatogenous Retinal Detachment Repair (2014) (0)
- Longitudinal Quantification of Retinal Nonperfusion in Eyes with Retinal Vein Occlusion Receiving Ranibizumab With or Without Targeted Peripheral Laser Photocoagulation (2017) (0)
- Reply. (2021) (0)
- Case presentations: CRVO and BRVO: BRVO in a patient with family history of glaucoma (2010) (0)
- Tyrosine Kinase Inhibition: A complete shut down of the neovascularization pathway is the goal (2010) (0)
- Longitudinal analysis of aqueous humour cytokine expression and OCT-based imaging biomarkers in retinal vein occlusions treated with anti-vascular endothelial growth factor therapy in the IMAGINE study. (2022) (0)
- New therapeutic targets in the management of Retinal Venous Occlusion (RVO) (2009) (0)
- Symptomatic vitreomacular adhesion (VMA): Diagnosis, pathologic implications, and management (2011) (0)
- Faculty Opinions recommendation of Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy. (2012) (0)
- HAWK Extension Study: Safety and Efficacy of Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With David M. Brown?
David M. Brown is affiliated with the following schools:
